Amitriptyline versus placebo for major depression

Research output: Contribution to journalJournal articleResearchpeer-review

Lars Vedel Kessing, Jens Otto Drachmann Bukh

A recent Cochrane review concluded that amitriptyline is an efficacious antidepressant drug, however associated with a number of side effects. The present paper discusses this finding in relation to studies on effects and side effects of SSRIs and dual-action drugs. It is concluded that there is some evidence for recommending treatment with tricyclic antidepressants (TCA) especially in patients who are hospitalized with severe depression and melancholic features. Further, nortriptylin is preferred due to its more favourable side effects profile.

Original languageDanish
JournalUgeskrift for Laeger
Issue number34
Pages (from-to)1875-1877
Number of pages3
Publication statusPublished - 19 Aug 2013

ID: 122662923